Ontario Institute for Cancer Research

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal add...

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NC...

Identification of human brain tumour initiating cells

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

A second generation human haplotype map of over 3.1 million SNPs

The landscape of somatic copy-number alteration across human cancers

The repertoire of mutational signatures in human cancer

International network of cancer genome projects

Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4

This report shows that cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) plays a key role in T cell–mediated dominant immunologic self-tolerance. In vivo blockade of CTLA-4 f...

ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia

Chromatin immunoprecipitation (ChIP) followed by high-throughput DNA sequencing (ChIP-seq) has become a valuable and widely used approach for mapping the genomic location of tra...